Best friends Joel and Matt are the co-hosts of How to Money which is all about providing the knowledge & tools that normal folks need to thrive in areas like debt payoff, DIY investing, and crucial money tricks that will provide continuous help along your journey. We believe that access to unbiased and jargon-free personal finance guidance is more necessary than ever before. When you handle your money in a purposeful, thoughtful way that works for your lifestyle, you can really start living ...
…
continue reading
Content provided by The Sunday Roast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Roast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S11 Ep22: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
MP3•Episode home
Manage episode 522437868 series 3002024
Content provided by The Sunday Roast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Roast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of the Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), to break down the major news that addiction candidate SVN-015 has been accepted into the US NIH/NIDA Addiction Treatment Discovery Program — opening the door to fully funded preclinical work and potentially up to $3m per year in non-dilutive grants. Anthony also discusses progress across Solvonis’ CNS pipeline, the company’s AI-powered discovery engine, and the widening valuation gap between UK and US biotech markets.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.
574 episodes
S11 Ep22: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
MP3•Episode home
Manage episode 522437868 series 3002024
Content provided by The Sunday Roast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Roast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of the Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), to break down the major news that addiction candidate SVN-015 has been accepted into the US NIH/NIDA Addiction Treatment Discovery Program — opening the door to fully funded preclinical work and potentially up to $3m per year in non-dilutive grants. Anthony also discusses progress across Solvonis’ CNS pipeline, the company’s AI-powered discovery engine, and the widening valuation gap between UK and US biotech markets.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.
574 episodes
Усі епізоди
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.